Trial Profile
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2024.
- 05 Jan 2021 Planned End Date changed from 1 Nov 2022 to 1 Nov 2024.
- 05 Jan 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2022.